Resources

Exenatide, a GLP-1 receptor agonist, improves glycemic control and body weight with twice daily or once weekly subcutaneous (SC) injections in patients with type 2 diabetes (T2DM)….

Type 2 diabetes mellitus (T2DM) often requires combination therapy to maintain glycemic control. Adding a sulfonylurea to metformin therapy improves glycemic control, but can cause hypoglycemia and weight gain. This 2-yr double-blind trial investigated the long-term efficacy and safety of adding linagliptin or glimepiride to ongoing metformin to treat T2DM….

This randomized, open-label, parallel-group, multicenter, 24-wk main treatment study, followed by a variable extension of at least 52 wk, compared the efficacy and safety of lixisenatide 20 µg QD and exenatide 10 µg BID in 634 T2DM patients insufficiently controlled on metformin ≥1.5 g/day (mean age 57.4 yr, diabetes duration …

The cardiovascular (CV) benefit of glucose lowering, particularly if too intensive, in type 2 diabetes mellitus (T2DM) is currently debated. Some modalities have even been reported, unexpectedly, to be associated with worse CV outcomes. To investigate the CV profile of the novel DPP-4 inhibitor linagliptin, a pre-specified meta-analysis of all …

Edited by Trisha Dunning AM, RN, MEd, PhD, CDE, FRCNA and Glenn Ward MBBS, BSc, DPhil (Oxon), FRACP, FRCPath   Mr. KM was referred to a diabetes center by his GP. Mr. KM is a 77-year-old man who has had type 2 diabetes for 17 years: current HbA1c 9.5%; random …

This week’s Homerun Slides cover eye diseases including Efferent Cranial Neuropathy, Glaucoma, AION and Retinal Vascular Occlusion….

By Sheri Colberg, PhD     It used to be common knowledge that you should stretch before and after physical activities for a variety of reasons.

With lawmakers and diabetes advocates ramping up the pressure, U.S. officials this week outlined a regulatory path for a preliminary version of the device….

Preventive treatment with metformin or lifestyle intervention in patients with type 2 diabetes reduced the cost of medical care, including costs for inpatient and outpatient care and prescriptions, compared with placebo….

Liraglutide, recently approved in the United States for the treatment of type 2 diabetes, has demonstrated its potential as a weight-loss drug for nondiabetic, obese patients….